Overview |
bs-3687R |
OGG1 Polyclonal Antibody |
WB, ELISA, FCM, IHC-P, IHC-F |
Human, Mouse, Rat |
Dog, Cow, Pig |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human OGG1/8 hydroxyguanine DNA glycosylase |
151-250/424 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
4968 |
Cytoplasm, Nucleus |
8 hydroxyguanine DNA glycosylase; 8 oxoguanine DNA glycosylase 1; 8-oxoguanine DNA glycosylase; AP lyase; DNA apurinic or apyrimidinic site lyase; DNA lyase; DNA-apurinic or apyrimidinic site lyase; HMMH; HOGG 1; HOGG1; MMH; MUTM; N-glycosylase; Ogg 1; OGH 1; OGH1; OGG1_HUMAN. |
This gene encodes the enzyme responsible for the excision of 8-oxoguanine, a mutagenic base byproduct which occurs as a result of exposure to reactive oxygen. The action of this enzyme includes lyase activity for chain cleavage. Alternative splicing of the C-terminal region of this gene classifies splice variants into two major groups, type 1 and type 2, depending on the last exon of the sequence. Type 1 alternative splice variants end with exon 7 and type 2 end with exon 8. All variants share the N-terminal region in common, which contains a mitochondrial targeting signal that is essential for mitochondrial localization. Many alternative splice variants for this gene have been described, but the full-length nature for every variant has not been determined. [provided by RefSeq, Aug 2008]. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
FCM |
1:20-100 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |